8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
Mar 3, 2026·SEC
Material company update
Dec 17, 2025·SEC
Immunome, Inc.(IMNM)Earnings, Financials & Key Ratios
IMNM•NASDAQ
Price updated Jun 19, 2026
AboutImmunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.Show more
- Revenue$7M-23.2%
- EBITDA-$211M+30.5%
- Net Income-$212M+27.5%
- EPS (Diluted)-2.43+51.4%
- Gross Margin57.43%-42.6%
- EBITDA Margin-3042.18%+9.4%
- Operating Margin-3084.76%+8.8%
- Net Margin-3059.99%+5.6%
- ROE-52.09%+73.2%
IMNM Key Insights
Immunome, Inc. (IMNM) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Profits declining 64.1% over 5 years
- ✗Negative free cash flow
- ✗Shares diluted 49.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when IMNM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
IMNM Price & Volume
Immunome, Inc. (IMNM) stock price & volume — 10-year historical chart
Loading chart...
IMNM Growth Metrics
Immunome, Inc. (IMNM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-63.29%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-9.5%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM24.84%
Return on Capital
10 Years-152.81%
5 Years-114.04%
3 Years-133.44%
Last Year-51.96%
IMNM Recent Earnings
Immunome, Inc. (IMNM) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 3/12 qtrs (38%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.48+20.0%
$0.60
Rev
—
$222,222
Q2 2026
Mar 3, 2026Metric
Actual
Est
EPS
$0.75-27.1%
$0.59
Rev
—
$876,034
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.65-14.0%
$0.57
Rev
—
$850,000
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$0.50+3.8%
$0.52
Rev
$4M+381.8%
$833,333
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.48vs $0.60+20.0% | —vs $222,222 |
| Q2 2026 | Mar 3, 2026 | $0.75vs $0.59-27.1% | —vs $876,034 |
| Q4 2025 | Nov 6, 2025 | $0.65vs $0.57-14.0% | —vs $850,000 |
| Q3 2025 | Aug 6, 2025 | $0.50vs $0.52+3.8% | $4Mvs $833,333+381.8% |
Based on last 12 quarters of dataView full earnings history →
IMNM Peer Comparison
Immunome, Inc. (IMNM) competitors in Drug Discovery and Antibody Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 | |
 AGEN | 124.93M | 3.00 | -882.35 | 10.37% | 52.16% | |||
 FATE | 243.61M | 2.09 | -1.82 | -51.24% | -20.57% | -58.89% | 0.38 | |
 MGNX | 262.52M | 4.13 | -3.50 | 0.78% | -44.79% | -147.8% | 1.92 | |
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 XNCR | 927M | 12.64 | -10.19 | 13.65% | -185.71% | -28.77% | 0.30 | |
 ALKS | 7.5B | 44.99 | 31.46 | -5.25% | 9.78% | 8.82% | 0.04 |
Compare IMNM vs Peers
Immunome, Inc. (IMNM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
IMNM Income Statement
Immunome, Inc. (IMNM) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 14.02M | 9.04M | 6.94M | 4.01M |
Revenue Growth % | - | - | - | - | - | - | -35.5% | -23.23% | -63.29% |
Cost of Goods Sold | 521K | 615K | 755K | 0 | 0 | 0 | 0 | 2.96M | 50.67M |
COGS % of Revenue | - | - | - | - | - | - | - | 42.57% | - |
Gross Profit | -521K▲ 0% | -615K▼ 18.0% | -755K▼ 22.8% | 0▲ 100.0% | 0▲ 0% | 14.02M▲ 0% | 9.04M▼ 35.5% | 3.99M▼ 55.9% | -46.65M▲ 0% |
Gross Margin % | - | - | - | - | - | 100% | 100% | 57.43% | -1161.92% |
Gross Profit Growth % | - | -18.04% | -22.76% | 100% | - | - | -35.5% | -55.91% | - |
Operating Expenses | 7.74M | 10.35M | 11.51M | 25.2M | 36.9M | 123.55M | 314.84M | 218.1M | 192.16M |
OpEx % of Revenue | - | - | - | - | - | 881.35% | 3482.37% | 3142.18% | - |
Selling, General & Admin | 866K | 1.52M | 4.78M | 11.09M | 13.63M | 19.66M | 32.95M | 43.77M | 46.03M |
SG&A % of Revenue | - | - | - | - | - | 140.23% | 364.51% | 630.57% | - |
Research & Development | 6.88M | 8.82M | 6.73M | 14.11M | 23.27M | 23.09M | 129.54M | 174.33M | 196.79M |
R&D % of Revenue | - | - | - | - | - | 164.71% | 1432.83% | 2511.61% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 80.8M | 152.34M | 0 | -2.47M |
Operating Income | -7.74M▲ 0% | -10.35M▼ 33.6% | -12.26M▼ 18.5% | -25.2M▼ 105.6% | -36.9M▼ 46.4% | -109.53M▼ 196.8% | -305.8M▼ 179.2% | -214.11M▲ 30.0% | -238.81M▲ 0% |
Operating Margin % | - | - | - | - | - | -781.35% | -3382.37% | -3084.76% | -5947.9% |
Operating Income Growth % | - | -33.64% | -18.49% | -105.56% | -46.41% | -196.82% | -179.19% | 29.98% | - |
EBITDA | -7.22M | -9.73M | -11.51M | -24.45M | -36.27M | -108.8M | -303.7M | -211.16M | -235.97M |
EBITDA Margin % | - | - | - | - | - | -776.16% | -3359.12% | -3042.18% | -5877.21% |
EBITDA Growth % | - | -34.77% | -18.22% | -112.49% | -48.35% | -199.98% | -179.13% | 30.47% | -9.46% |
D&A (Non-Cash Add-back) | 521K | 615K | 755K | 755K | 631K | 728K | 2.1M | 2.96M | 2.84M |
EBIT | -7.7M | -10.34M | -17.8M | -25.2M | -36.9M | -28.73M | -153.46M | -214.11M | -236.13M |
Net Interest Income | -102K | -96K | -37K | 0 | 0 | 2.72M | 12.84M | 11.72M | 14.21M |
Interest Income | 39K | 10K | 1K | 10K | 5K | 2.72M | 12.84M | 11.72M | 14.21M |
Interest Expense | 141K | 106K | 38K | 10K | 5K | 0 | 0 | 0 | 0 |
Other Income/Expense | -102K | -96K | -5.58M | 493K | 5K | 2.72M | 12.84M | 1.72M | 14.21M |
Pretax Income | -7.84M▲ 0% | -10.44M▼ 33.1% | -17.84M▼ 70.8% | -24.71M▼ 38.5% | -36.9M▼ 49.3% | -106.81M▼ 189.5% | -292.96M▼ 174.3% | -212.39M▲ 27.5% | -224.59M▲ 0% |
Pretax Margin % | - | - | - | - | - | -761.92% | -3240.38% | -3059.99% | -5593.85% |
Income Tax | 39K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | -0.5% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -7.84M▲ 0% | -10.55M▼ 34.5% | -17.84M▼ 69.1% | -24.71M▼ 38.5% | -36.9M▼ 49.3% | -106.81M▼ 189.5% | -292.96M▼ 174.3% | -212.39M▲ 27.5% | -224.59M▲ 0% |
Net Margin % | - | - | - | - | - | -761.92% | -3240.38% | -3059.99% | -5593.85% |
Net Income Growth % | - | -34.48% | -69.07% | -38.54% | -49.31% | -189.48% | -174.29% | 27.5% | -9.5% |
Net Income (Continuing) | -7.84M | -10.44M | -17.84M | -24.71M | -36.9M | -106.81M | -292.96M | -212.39M | -224.59M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -7.18▲ 0% | -1.84▲ 74.4% | -1.69▲ 8.2% | -2.14▼ 26.6% | -3.09▼ 44.4% | -5.38▼ 74.1% | -5.00▲ 7.1% | -2.43▲ 51.4% | -1.99▲ 0% |
EPS Growth % | - | 74.37% | 8.15% | -26.63% | -44.39% | -74.11% | 7.06% | 51.4% | 24.84% |
EPS (Basic) | -7.18 | -1.84 | -1.69 | -2.14 | -3.09 | -5.38 | -5.00 | -2.43 | - |
Diluted Shares Outstanding | 1.09M | 5.74M | 10.11M | 11.54M | 12.13M | 19.84M | 58.64M | 87.35M | 113.14M |
Basic Shares Outstanding | 1.09M | 5.74M | 10.11M | 11.54M | 12.13M | 19.84M | 58.64M | 87.35M | 113.14M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
IMNM Balance Sheet
Immunome, Inc. (IMNM) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 2.11M | 3.12M | 42.89M | 56.64M | 22.65M | 144.7M | 221.34M | 660.78M | 594.31M |
Cash & Short-Term Investments | 1.6M | 2.54M | 39.77M | 49.23M | 20.32M | 138.14M | 217.3M | 653.48M | 582.69M |
Cash Only | 1.6M | 2.54M | 39.77M | 49.23M | 20.32M | 98.68M | 143.35M | 653.48M | 582.69M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 39.46M | 73.95M | 0 | 0 |
Accounts Receivable | 0 | 0 | 850K | 4.31M | 847K | 289K | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | 7.53 | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
Other Current Assets | 509K | 0 | 0 | 0 | 0 | 4.99M | 4.04M | 7.29M | 11.62M |
Total Non-Current Assets | 2.34M | 1.94M | 1.63M | 1.29M | 1.4M | 3.84M | 18.9M | 22.41M | 25.48M |
Property, Plant & Equipment | 2.08M | 1.7M | 1.53M | 855K | 965K | 3.64M | 14.39M | 17.61M | 19.91M |
Fixed Asset Turnover | - | - | - | - | - | 3.85x | 0.63x | 0.39x | 0.24x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 100K | 0 | 100K | 100K | 0 | 100K | 0 | 210K | 210K |
Other Non-Current Assets | 155K | 238K | 0 | 332K | 432K | 100K | 4.51M | 4.59M | 5.57M |
Total Assets | 4.45M▲ 0% | 5.06M▲ 13.8% | 44.52M▲ 779.9% | 57.92M▲ 30.1% | 24.05M▼ 58.5% | 148.54M▲ 517.7% | 240.24M▲ 61.7% | 683.19M▲ 184.4% | 619.79M▲ 0% |
Asset Turnover | - | - | - | - | - | 0.09x | 0.04x | 0.01x | 0.01x |
Asset Growth % | - | 13.76% | 779.94% | 30.1% | -58.49% | 517.73% | 61.73% | 184.38% | 281.8% |
Total Current Liabilities | 1.56M | 1.67M | 3.04M | 9.73M | 7.33M | 21.83M | 54.31M | 44.99M | 27.41M |
Accounts Payable | 473K | 548K | 1.19M | 3.08M | 2.4M | 3.31M | 14.19M | 3.34M | 5.53M |
Days Payables Outstanding | 331.37 | 325.24 | 573.85 | - | - | - | - | 412.43 | 35.44 |
Short-Term Debt | 225K | 212K | 479K | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 10.49M | 6.94M | 0 | 0 |
Other Current Liabilities | 83K | 426K | 527K | 2.02M | 1.96M | 4.98M | 8M | 41.65M | 21.88M |
Current Ratio | 1.35x | 1.88x | 14.12x | 5.82x | 3.09x | 6.63x | 4.08x | 14.69x | 21.68x |
Quick Ratio | 1.35x | 1.88x | 14.12x | 5.82x | 3.09x | 6.63x | 4.08x | 14.69x | 21.68x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 28.09M | 39.02M | 142K | 12K | 62K | 6.83M | 4.77M | 3.85M | 3.69M |
Long-Term Debt | 325K | 113K | 134K | 0 | 0 | 0 | 0 | 3.85M | 3.69M |
Capital Lease Obligations | 239K | 0 | 0 | 0 | 62K | 1.34M | 4.77M | 0 | 4.14M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | -5.49M | 0 | 0 | 0 |
Other Non-Current Liabilities | 27.53M | 38.91M | 8K | 12K | 0 | 5.49M | 0 | 0 | 0 |
Total Liabilities | 29.65M | 40.69M | 3.18M | 9.74M | 7.39M | 28.66M | 59.08M | 48.84M | 31.11M |
Total Debt | 1.18M | 564K | 613K | 317K | 291K | 1.65M | 4.83M | 3.85M | 3.69M |
Net Debt | -426K | -1.98M | -39.15M | -48.91M | -20.03M | -97.03M | -138.52M | -649.63M | -579M |
Debt / Equity | - | - | 0.01x | 0.01x | 0.02x | 0.01x | 0.03x | 0.01x | 0.01x |
Debt / EBITDA | - | - | - | - | - | - | - | - | -0.02x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | 2.45x |
Interest Coverage | -54.64x | -97.53x | -468.37x | -2520.40x | -7380.20x | - | - | - | - |
Total Equity | -25.2M▲ 0% | -35.63M▼ 41.4% | 41.34M▲ 216.0% | 48.19M▲ 16.5% | 16.65M▼ 65.4% | 119.88M▲ 619.9% | 181.16M▲ 51.1% | 634.34M▲ 250.1% | 588.69M▲ 0% |
Equity Growth % | - | -41.36% | 216.04% | 16.54% | -65.44% | 619.88% | 51.12% | 250.15% | 370.71% |
Book Value per Share | -23.07 | -6.20 | 4.09 | 4.18 | 1.37 | 6.04 | 3.09 | 7.26 | 5.20 |
Total Shareholders' Equity | -25.2M | -35.63M | 41.34M | 48.19M | 16.65M | 119.88M | 181.16M | 634.34M | 588.69M |
Common Stock | 1K | 0 | 1K | 1K | 1K | 4K | 6K | 11K | 11K |
Retained Earnings | -26.11M | -36.56M | -54.39M | -79.11M | -116M | -222.81M | -515.77M | -728.16M | -782M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -904K | 0 | -44.52M | -57.92M | 0 | 22K | 57K | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IMNM Cash Flow Statement
Immunome, Inc. (IMNM) cash flow — operating, investing & free cash flow history
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -7.41M | -9.6M | -12.13M | -18.23M | -28.69M | -7.57M | -110.79M | -190.92M | -196.5M |
Operating CF Margin % | - | - | - | - | - | -53.99% | -1225.46% | -2750.6% | - |
Operating CF Growth % | - | -29.62% | -26.4% | -50.21% | -57.41% | 73.62% | -1363.98% | -72.32% | -154.24% |
Net Income | -7.84M | -10.44M | -17.84M | -24.71M | -36.9M | -106.81M | -292.96M | -212.39M | -224.59M |
Depreciation & Amortization | 521K | 615K | 755K | 755K | 631K | 728K | 2.1M | 2.96M | 2.98M |
Stock-Based Compensation | 11K | 14K | 621K | 3.45M | 5.33M | 6.22M | 15.75M | 25.69M | 19.99M |
Deferred Taxes | 0 | 0 | 5.54M | -500K | -7.27M | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 9K | 3K | -2K | 4K | 7.27M | 80.29M | 149.44M | 8.06M | 16.91M |
Working Capital Changes | -102K | 212K | -1.21M | 2.78M | 2.24M | 12M | 14.87M | -15.23M | -11.79M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 146K | 75K | 504K | 1.78M | -677K | -608K | 9.53M | -9.16M | -3.93M |
Cash from Investing | -228K | -233K | -586K | -79K | -248K | -30.48M | -85.06M | 60.8M | 43.7M |
Capital Expenditures | -228K | -233K | -586K | -79K | -248K | -831K | -7.17M | -9.69M | -9.02M |
CapEx % of Revenue | - | - | - | - | - | 5.93% | 79.34% | 139.53% | 224.71% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 9.28M | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | -46.34M | -6.25M | -9.01M |
Cash from Financing | -551K | 10.77M | 49.94M | 27.77M | 32K | 116.41M | 240.53M | 640.36M | 477.99M |
Debt Issued (Net) | -551K | 6.19M | 49K | -113K | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 0 | 4.59M | 55.9M | 27.23M | 32K | 34K | 250M | 640.36M | 477.99M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | -35K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | -6M | 656K | 0 | 116.37M | -9.47M | 0 | 0 |
Net Change in Cash | -8.19M▲ 0% | 941K▲ 111.5% | 37.22M▲ 3855.7% | 9.46M▼ 74.6% | -28.91M▼ 405.5% | 78.36M▲ 371.1% | 44.67M▼ 43.0% | 510.24M▲ 1042.2% | 325.19M▲ 0% |
Free Cash Flow | -7.63M▲ 0% | -9.83M▼ 28.8% | -12.72M▼ 29.4% | -18.3M▼ 43.9% | -28.94M▼ 58.1% | -8.4M▲ 71.0% | -164.3M▼ 1856.2% | -200.6M▼ 22.1% | -205.52M▲ 0% |
FCF Margin % | - | - | - | - | - | -59.92% | -1817.3% | -2890.13% | -5118.9% |
FCF Growth % | - | -28.81% | -29.36% | -43.91% | -58.09% | 70.98% | -1856.21% | -22.09% | -27.18% |
FCF per Share | -6.99 | -1.71 | -1.26 | -1.59 | -2.39 | -0.42 | -2.80 | -2.30 | -1.82 |
FCF Conversion (FCF/Net Income) | 0.94x | 0.91x | 0.68x | 0.74x | 0.78x | 0.07x | 0.38x | 0.90x | 0.92x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IMNM Key Ratios
Immunome, Inc. (IMNM) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -624.22% | -55.2% | -113.81% | -156.45% | -194.63% | -52.09% | -51.15% |
Return on Invested Capital (ROIC) | - | - | -2580.61% | - | -843.66% | -700.32% | -1173.78% | -600.87% |
Gross Margin | - | - | - | - | 100% | 100% | 57.43% | -1161.92% |
Net Margin | - | - | - | - | -761.92% | -3240.38% | -3059.99% | -5593.85% |
Debt / Equity | - | 0.01x | 0.01x | 0.02x | 0.01x | 0.03x | 0.01x | 0.01x |
Interest Coverage | -97.53x | -468.37x | -2520.40x | -7380.20x | - | - | - | - |
FCF Conversion | 0.91x | 0.68x | 0.74x | 0.78x | 0.07x | 0.38x | 0.90x | 0.92x |
Revenue Growth | - | - | - | - | - | -35.5% | -23.23% | -63.29% |
Related:IMNM Dividend History·IMNM Revenue History·IMNM Price History·IMNM P/E History·IMNM Financial Ratios·IMNM Institutional Holders
IMNM SEC Filings & Documents
Immunome, Inc. (IMNM) SEC filings — annual & quarterly reports (10-K, 10-Q)
IMNM Frequently Asked Questions
Immunome, Inc. (IMNM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Immunome, Inc. (IMNM) reported $4.0M in revenue for fiscal year 2025.
Immunome, Inc. (IMNM) saw revenue decline by 23.2% over the past year.
Immunome, Inc. (IMNM) reported a net loss of $224.6M for fiscal year 2025.
Dividend & Returns
Immunome, Inc. (IMNM) has a return on equity (ROE) of -52.1%. Negative ROE indicates the company is unprofitable.
Immunome, Inc. (IMNM) had negative free cash flow of $205.5M in fiscal year 2025, likely due to heavy capital investments.